Difference between revisions of "Ropeginterferon alfa-2b (Besremi)"
m |
m |
||
Line 14: | Line 14: | ||
*2023-03-27: Initial approval | *2023-03-27: Initial approval | ||
==Also known as== | ==Also known as== | ||
− | *'''Code name:''' | + | *'''Code name:''' AOP-2014 |
*'''Generic name:''' ropeginterferon alfa-2b-njft | *'''Generic name:''' ropeginterferon alfa-2b-njft | ||
*'''Brand name:''' Besremi | *'''Brand name:''' Besremi |
Revision as of 00:54, 30 July 2023
General information
Class/mechanism per NCI Drug Dictionary: A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b) protein, in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon subcutaneous administration, IFN-a2b binds to specific interferon cell-surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs); the protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a predominant (90%) positional isomer which allows for further increases in stability and a longer half-life than previous PEG conjugates.
Route: SC
Extravasation: n/a
Diseases for which it is used
History of changes in FDA indication
- 2021-11-12: Initial approval for adults with polycythemia vera. (Based on PEGINVERA)
History of changes in EMA indication
- 2019-02-15: Initial authorization
History of changes in PMDA indication
- 2023-03-27: Initial approval
Also known as
- Code name: AOP-2014
- Generic name: ropeginterferon alfa-2b-njft
- Brand name: Besremi